Administration of MabThera for rheumatoid arthritis
The summary of product characteristics (SPC) for MabThera (rituximab; Roche) now states that there is an alternative faster infusing schedule for the second or subsequent dose of the drug in patients with rheumatoid arthritis who did not have a serious adverse reaction to the first or subsequent doses. Detailed information about this alternative infusion schedule is included in the updated SPC.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066641
Recommended from Pharmaceutical Press
All you need to know about prescribing or administering drugs via enteral feeding tubes. Over 400 drug monographs as well as facts to inform clinical decision making.£54.00Buy now